Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
Sumati Gupta(University of Utah), S. Sharma(University of Utah), Alexis Weston(Translational Genomics Research Institute), Raffaella Soldi(Translational Genomics Research Institute), Adrianne Neiss(University of Utah), Trason Thode(Translational Genomics Research Institute), Jared Bearrs(University of Utah)
Cited by 47
Related Papers
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
|Oncotarget|2018|27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma
|Molecular Cancer Therapeutics|2018|24
Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway
|Cancer Research|2019|19
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2020|19